Eylea 8 mg is being jointly developed by Bayer and Regeneron. Regeneron maintains exclusive rights to Eylea 2 mg and Eylea HD in the United States.

So a very meaningful expansion opportunity for EYLEA HD and potentially could be the only product approved with every 8-week dosing. And lastly, every 4-week dosing is another label enhancement we ...

Eylea HD should also earn some label expansions. Meanwhile, Regeneron's other growth driver is Dupixent, a medicine for eczema. It shares the rights to Dupixent with Sanofi.

Our Top 5 Analyst Questions Regeneron’s Q1 Earnings Call Tyler Van Buren (TD Cowen) asked about the timeline and specifics behind the EYLEA HD pre-filled syringe regulatory delay.

Regeneron has faced several regulatory setbacks in recent months, including the Complete Response Letter for Eylea HD’s pre-filled syringe. These challenges raise questions about the company’s ability ...

Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label expansions for its main product as well as clinical progress elsewhere. Here ...

Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar ...

The study met its primary endpoint, with results demonstrating therapeutic equivalence between Alvotech’s biosimilar candidate and Eylea® [2]. Alvotech is also developing AVT29, a proposed biosimilar ...

This helps to explain why patients are favoring Vabysmo - less frequent dosing, although Regeneron has launched Eylea HD, which has the potential for 16-week dosing intervals.